Alamar Biosciences
Alamar Biosciences, headquartered in Fremont, California, specializes in ultra-high sensitivity protein analysis and precision proteomics, having raised nearly $250 million in total funding.
Funding and Capital
Alamar Biosciences has successfully raised $128 million in an oversubscribed Series C financing round. This recent injection of capital brings the total amount raised by the company to nearly $250 million. This substantial funding supports their ongoing efforts in developing innovative proteomic technologies and expanding their commercial footprint in the precision medicine market.
Products and Assays
Alamar Biosciences offers several advanced products for ultra-high sensitivity protein analysis. Their product lineup includes the NULISAseq CNS Disease Panel 120 and NULISAqpcr pTau-217 Assays. These assays are designed to provide precise and sensitive quantification of proteins, addressing critical needs in neurodegenerative disease research and diagnostics.
Advanced Proteomics Platform
The ARGO HT System is one of Alamar Biosciences' flagship products. It is a fully automated, high-throughput precision proteomics platform that enables large-scale proteomic studies with high data quality and reproducibility. Additionally, Alamar has developed the NULISA Platform, which offers attomolar sensitivity and scalable multiplexing, providing robust and detailed proteomic analysis capabilities.
Disease and Inflammation Panels
Alamar Biosciences has launched the NULISAseq Inflammation Panel 250, specifically designed for deep profiling of immune responses. This panel complements their existing NULISAseq CNS Disease Panel 120, enabling researchers to gain a comprehensive understanding of the molecular and cellular mechanisms underlying inflammatory and central nervous system diseases.
Strategic Partnerships
Alamar Biosciences has entered into a strategic partnership with Biognosys. This collaboration aims to advance research in the fields of biopharma and precision medicine. By leveraging Biognosys' expertise in proteomics and data analysis, the partnership seeks to enhance Alamar's technological capabilities and broaden the application of their proteomic platforms.
Headquarters
Alamar Biosciences is headquartered in Fremont, California, which is located in the heart of Silicon Valley. This strategic location places the company within one of the world's leading hubs for technology and innovation, providing access to cutting-edge research, resources, and a highly skilled workforce.